CASI Pharmaceuticals (CASIF) Income from Continuing Operations (2022 - 2025)
CASI Pharmaceuticals' (CASIF) quarterly Income from Continuing Operations came in at 77548000.0 in Q4 2025, down 495.74% YoY from 19595494.74 in Q4 2024, and down 626.99% on a QoQ basis from 10667000.0 in Q3 2025.
CASI Pharmaceuticals (CASIF) Income from Continuing Operations (2022 - 2025) Analysis & Trends
CASI Pharmaceuticals (CASIF) has 4 years of Income from Continuing Operations data on file, last reported at 77548000.0 in Q4 2025.
- Quarterly Income from Continuing Operations fell 495.74% year-over-year to 77548000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 109597000.0 (down 178.77% YoY) and the FY2025 annual result came in at 8568000.0, up 77.82% from the prior year.
- Income from Continuing Operations retreated to 77548000.0 in Q4 2025, from 10667000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 5095000.0 in Q3 2023 to a low of 100472000.0 in Q4 2022.
- A 4-year average of 22175625.0 and a median of 9334000.0 in 2023 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations jumped 79.88% — and 2025, when it slumped 495.74%.
- Tracing CASIF's Income from Continuing Operations over 4 years: stood at 100472000.0 in 2022, then soared by 35.6% to 64708000.0 in 2023, then soared by 79.88% to 13017000.0 in 2024, then tumbled by 495.74% to 77548000.0 in 2025.
- The last three Income from Continuing Operations figures came in at 77548000.0 (Q4 2025), 10667000.0 (Q3 2025), and 11080000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | CASI Pharmaceuticals | 2.65 Mn | -3.76 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -77.55 Mn |
| Sep 30, 2025 | -10.67 Mn |
| Jun 30, 2025 | -11.08 Mn |
| Mar 31, 2025 | -10.30 Mn |
| Dec 31, 2024 | -13.02 Mn |
| Sep 30, 2024 | -8.32 Mn |
| Jun 30, 2024 | -8.65 Mn |
| Mar 31, 2024 | -9.32 Mn |
| Dec 31, 2023 | -64.71 Mn |
| Sep 30, 2023 | -5.10 Mn |
| Jun 30, 2023 | -9.35 Mn |
| Mar 31, 2023 | -7.21 Mn |
| Dec 31, 2022 | -100.47 Mn |
| Sep 30, 2022 | -5.72 Mn |
| Jun 30, 2022 | -6.39 Mn |
| Mar 31, 2022 | -6.96 Mn |